The analysis is not a head-to-head trial, and the weight loss gap reached statistical significance under 1 of 2 estimands.
|Articles|November 27, 2007
Hay fever nasal spray expands its population base
More pediatric patients can now use Omnaris Nasal Spray for hay fever
Advertisement
Nycomed's Omnaris (ciclesonide) Nasal Spray, previously approved to treat seasonal allergic rhinitis in adults and patients 12 years of age and older, can now be used by kids as young as six. The hay fever treatment is a corticosteroid.
To see more Daily News articles,
To go to the Drug Topics homepage,
To see more Daily News articles,
To go to the Drug Topics homepage,
Advertisement
Related to this article
A 1.6-million-birth analysis finds that adoption of a 2016 trial's antibiotic protocol climbed sharply in US hospitals, with a drop in infection rates.
New findings suggest semaglutide's benefits may extend well beyond diabetes and weight loss and into airway disease and mood disorders.
First approved for adults in 2022, the therapy is now cleared for adults and pediatric patients weighing 66 lbs or more with symptomatic obstructive hypertrophic cardiomyopathy.
With the inherent value medications provide in the greater health care system, Jennifer Hammons, PharmD, DrPH, argues that rural pharmacies deserve the proper recognition.
A claims analysis of 2031 patients aged 10 to 17 years found that nutrition counseling was infrequent and often began months after treatment started.
Community pharmacists offer accessible care, improve medication adherence, and build trust through education, vaccination support, and local health leadership.
Researchers compared vaccine coadministration with single-dose, sequential vaccination for the RSVPreF3 OA vaccine formulation in adults.
Advertisement
Advertisement
Trending on Drug Topics
1
What Is HIV PrEP and Who Needs It Most?
2
Indirect Comparison Links Tirzepatide to Greater Weight Loss Than Semaglutide
3
Normal vs. Concerning COVID-19 Vaccine Reactions: A Pharmacist's Guide
4
Validating Fear Before Facts: A Framework for COVID-19 Hesitancy
5